Clinical trials
Breast Cancer Risk clinical trials
Below are recruiting breast cancer risk clinical trials, each written for real people, not researchers. We’re tracking 740 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07151911Recruiting
Study of drugs for high-risk early breast cancer
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
Modena, ModenaAges 18 years+ - NCT07142096Recruiting
MitoQ before surgery for triple-negative breast cancer
This trial tests whether taking the supplement MitoQ before standard surgery can help treat triple-negative breast cancer. You would take MitoQ for a short time between diagnosis and surgery to see if it slows tumor growth.
BrusselsAges 18 years+ - NCT06962670Recruiting
Cancer risk study using digital and molecular markers
This study uses a smartphone app and biological markers to predict cancer risk. It is testing whether digital and molecular data can help identify cancer earlier, especially in women with a history of certain cancers.
Please Refer to Project Homepage For Details (see Link Below), BavariaAges 18 years+ - NCT07121972Recruiting
Validating AI for breast cancer risk prediction
This trial uses an AI model called Mirai to identify women at high risk for breast cancer based on their mammograms. If you are eligible, you may be invited for a breast MRI to better understand your risk.
San Diego, CaliforniaAges 40–89 - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07120087Recruiting
Online program to lower breast cancer risk for high-risk women
This trial tests an online program that teaches women at high risk of breast cancer how to lower their risk. If you were part of the MyPeBS study and found to have high risk, this program might help you take steps to protect your health.
LyonAges 40–74 - NCT07120100Recruiting
TMS for nerve pain from cancer chemo in breast/gyne cancer survivors
This trial tests if transcranial magnetic stimulation (TMS), a noninvasive brain treatment, can reduce nerve pain caused by chemotherapy in women who have had breast or gynecologic cancer. You may be eligible if you have ongoing nerve pain that hasn't been helped by standard pain medications.
Salt Lake City, UtahAges 18 years+ - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
Huntsville, AlabamaAges 18 years+ - NCT03201861RecruitingPhase 3
Cisplatin added after surgery for high-risk breast cancer
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05362760RecruitingPhase 4
Abemaciclib plus hormone therapy, with digital side-effect tracking
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
AalenAges 18 years+ - NCT07076147Recruiting
Breast cancer screening follow-up for moderate-risk women
This study looks at how well women with a moderate risk of breast cancer follow their screening recommendations (like yearly MRI or mammogram). It may help women who have certain genetic variants or a higher calculated risk stay on top of their breast health.
Los Angeles, CaliforniaAges 30–75 - NCT07084571Recruiting
Testing Tissue Sampling Over Time in Advanced Breast Cancer
This study is testing whether it is safe and practical to take multiple small tissue samples (biopsies) from different sites of your breast cancer over time. The goal is to learn how breast cancer changes as it grows, which could help doctors develop better treatments.
LondonAges 18 years+ - NCT07076485RecruitingPhase 2
Shorter radiation after surgery for node-positive breast cancer
This trial tests shorter radiation schedules for people with breast cancer that has spread to lymph nodes or is high-risk. It aims to find a shorter course of radiation that is just as effective after surgery.
Loveland, ColoradoAges 18 years+ - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT07070128Recruiting
AI screening tool for breast cancer genetic risk
This trial tests an AI tool that predicts genetic risk for breast cancer. It may help women identified as high-risk by their breast surgeon get quicker genetic counseling.
Golania, GoiásAges Any age - NCT05333328RecruitingPhase 4
Test of ovarian function suppression for low-risk premenopausal node+ breast cancer
This trial studies whether ovarian function suppression (a treatment that lowers hormone production from the ovaries) helps women with hormone-receptor positive, HER2-negative breast cancer that has spread to lymph nodes, but who have a low-risk result on a genomic test. It may help reduce breast cancer recurrence while avoiding more intensive treatment for those who are lower risk.
Seoul, KoreaAges 20–50 - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT07039552Recruiting
Ovarian cancer risk check for family members
This study looks at family members of people with ovarian cancer to build a better tool for predicting their risk. If you have a BRCA1 or BRCA2 gene mutation, you may be able to join.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07024173RecruitingPhase 3
HRS-8080 versus doctor's choice for advanced breast cancer
This trial tests a new medicine called HRS-8080 for locally advanced or metastatic breast cancer. It compares HRS-8080 with whatever treatment your doctor would normally choose for you.
Guangzhou, GuangdongAges 18–75 - NCT07019363RecruitingPhase 3
CDK4/6 inhibitor plus hormone therapy for high-risk breast cancer
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
ShanghaiAges 18–70 - NCT07021846Recruiting
Higher-dose radiation for early breast cancer in young women
This study tests a higher-dose, faster radiation treatment for young women with early breast cancer who have certain risk factors. The goal is to reduce the chance of cancer coming back while keeping side effects low.
RomaAges 18–50 - NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2-positive breast cancer
This study tests an experimental drug called evorpacept when given with trastuzumab and chemotherapy for people with HER2-positive breast cancer that has spread. The goal is to see if this combination can shrink tumors or slow down the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Gilbert, ArizonaAges 18 years+
Hear when a new Breast Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer risk?
- Yes. Clin2 currently lists 740 recruiting breast cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.